文献速递真菌感染

肥胖时代静脉泊沙康唑给药剂量建议

Implications for IV posaconazole dosing in the era of obesity.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该前瞻性研究纳入16例病态肥胖和8例正常体重受试者,体重61.4-190 kg,静脉给予300或400 mg泊沙康唑后进行群体药动学建模。结果显示总体重最能预测清除率和表观分布容积变化,治疗性用药时体重超过140 kg需将负荷和维持剂量增至400 mg,预防性用药300 mg对190 kg以下患者足够。

要点

  • 治疗性静脉泊沙康唑:体重≤140 kg每日300 mg,>140 kg需增至400 mg(负荷和维持)。
  • 预防性静脉泊沙康唑:300 mg剂量对体重≤190 kg患者足够。
  • 口服治疗可参考上述剂量作为起点,并进行治疗药物监测。

核心结论

  • 体重显著影响泊沙康唑清除率和表观分布容积,肥胖受试者暴露量低于正常体重者。
  • 治疗性静脉泊沙康唑在体重>140 kg患者中需增加剂量至400 mg,预防性300 mg对≤190 kg足够。

研究设计与样本

  • 前瞻性研究,纳入病态肥胖16例和正常体重8例受试者,体重范围61.4-190 kg,静脉给予300或400 mg泊沙康唑。
  • 采用群体药动学建模评估体形对泊沙康唑药动学的影响,ClinicalTrials.gov注册号NCT03246386。

主要发现

  • 总体重最能预测清除率和表观分布容积的变化。
  • 模型模拟显示,治疗真菌感染时每日静脉300 mg在体重≤140 kg个体中可达PTA≥90%,超过140 kg后需将负荷和维持剂量增至400 mg。
  • 预防用药时300 mg静脉剂量对体重≤190 kg患者足够。

关键数值与推荐

  • 治疗性静脉泊沙康唑:体重≤140 kg每日300 mg可达PTA≥90%;体重>140 kg需将负荷和维持剂量增至400 mg。
  • 预防性静脉泊沙康唑:300 mg剂量对体重≤190 kg患者足够。
  • 口服治疗可以上述推荐为起点,并进行治疗药物监测。

临床怎么用

  • 肥胖患者使用静脉泊沙康唑治疗真菌感染时,应依据体重调整剂量,>140 kg者需增加至400 mg。
  • 预防性用药可维持300 mg静脉剂量,无需因体重≤190 kg而常规增量。
  • 口服泊沙康唑治疗可参考静脉推荐作为初始剂量,并借助治疗药物监测优化暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of obesity has shown a dramatic increase over recent decades. Obesity is associated with underdosing of antimicrobial drugs for prophylaxis and treatment. Posaconazole is a broad-spectrum triazole antifungal drug licensed for prophylaxis and treatment of invasive fungal infections. It is unclear how posaconazole should be dosed in obese patients. METHODS: We performed a prospective study investigating the pharmacokinetics of posaconazole in morbidly obese (n = 16) and normal-weight (n = 8) subjects, with a weight ranging between 61.4 and 190 kg, after a 300 or 400 mg IV dose. Population pharmacokinetic modelling was used to assess the effect of body size on posaconazole pharmacokinetics. ClinicalTrials.gov Identifier: NCT03246386. RESULTS: Total body weight best predicted changes in CL and V. Model-based simulations demonstrated that, for treatment of fungal infections, a daily IV dose of 300 mg will result in a PTA of ≥90% in individuals up to 140 kg, after which both twice daily loading and the daily maintenance dose should be increased to 400 mg. For prophylaxis, a 300 mg IV dose is adequate in patients up to 190 kg. CONCLUSIONS: Body size has a significant impact on posaconazole CL and V, resulting in a lower exposure in obese subjects compared with normal-weight subjects. For therapeutic use of posaconazole, a dose increase is required in patients above 140 kg. For prophylaxis, a 300 mg IV dose is adequate. For oral treatment, these recommendations can act as a starting point followed by therapeutic drug monitoring.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wasmann RE, Smit C, van Donselaar MH, et al. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020. PMID: 31971567. doi:10.1093/jac/dkz546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。